Palisade Bio (PALI) said Friday it began dosing ulcerative colitis patients in the final cohort of its phase 1a/b study of PALI-2108.
The company said it had completed five single ascending dose cohorts and three of four multiple ascending dose cohorts, with no serious adverse events or treatment-related adverse events tied to lab results or EKGs.
Palisade Bio said it plans to report topline data in H1.
Shares of the company were up 3% in recent Friday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。